Sunstone Therapies presents data at ASCO showing positive long-term follow-up results from psilocybin therapy in cancer patients with major depressive disorder (MDD) 18-month follow-up of patients in phase 2 study shows continued robust clinical response to psilocybin therapy, with sustained response in 64% of patients and two-thirds of patients in remission Data presented at ASCO […]
- May 2023
- New York, May 26, 2023 /PRNewswire/ — Terran Biosciences (“Terran”), a biotech platform company dedicated to the development of transformational therapeutics for neurological and psychiatric diseases, has announced the publication of a PCT patent application covering what may be the first comprehensive salt and polymorph screens of the empathogens MDMA, (R)-MDMA, (S)-MDMA, MDEA (MDE), (S)-MDEA, (R)-MDEA, […]
- More than half of the patients demonstrated remission of depression at 18 months, after a single dose of 25mg investigational COMP360 psilocybin with psychological support Open label phase 2 study, conducted by Sunstone Therapies and scheduled to be presented at the ASCO annual meeting on June 5, is believed to be the longest clinical study […]
A group of activist investors are trying to take control of MindMed’s board of directors. Today, MindMed has pushed back, potentially dealing a final blow to this increasingly suspect attempted coup.
The post MindMed Publishes Report by FDA Experts: Is FCM’s Takeover Attempt Over? appeared first on Microdose.
- No more posts to load